Table 6.

Major trials in HCC involving oncolytic viruses-based immunotherapies.

Name	Phase	Line of Treatment	Strategy	Primary Endpoint
NCT03071094	1/2		Pexastimogene Devacirepvec (Pexa Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells) + Nivolumab (anti PD-1/PD-L1)	Safety DLT (Dose Limiting Toxicity) Anti-tumor activity Efficacy
NCT02562755	3		Pexa-Vec + Sorafenib (Raf inhibitor)	OS (Overall Survival)